CTOs on the Move

GW Pharmaceuticals

www.gwpharm.com

 
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.gwpharm.com
  • 5750 Fleet Street Suite 200
    Carlsbad, CA USA 92008
  • Phone: 760.795.2200

Executives

Name Title Contact Details

Similar Companies

CPEX Pharmaceuticals

CPEX Pharmaceuticals is a Exeter, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Recovery & Wellness Center

Sage Recovery & Wellness Center Austin is an outpatient center specializing in both mental health and substance use, utilizing a holistic approach to recovery.

Abivax

Abivax is a clinical stage biopharmaceutical company that focuses on developing treatments for inflammatory diseases, viral infections, and cancer by modulating the bodys natural immune system machinery.

Integrated BioPharma

Integrated BioPharma is a Hillside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.